The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Rituximab Biosimilars Market Research Report 2025
Synopsis
The global Rituximab Biosimilars market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Rituximab Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rituximab Biosimilars.
Report Scope
The Rituximab Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rituximab Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rituximab Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
AryoGen Pharmed
Biocad
Cadila Pharmaceuticals
Celltrion
Dr Reddy’s Laboratories
Teva
Hetero Group
Innovent Biologics
Intas Biopharmaceuticals
Mylan
Probiomed
TRPharma
Zenotech Laboratories
Segment by Type
500mg
100mg
Other
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Rituximab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Rituximab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Rituximab Biosimilars market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Rituximab Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rituximab Biosimilars.
Report Scope
The Rituximab Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rituximab Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rituximab Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
AryoGen Pharmed
Biocad
Cadila Pharmaceuticals
Celltrion
Dr Reddy’s Laboratories
Teva
Hetero Group
Innovent Biologics
Intas Biopharmaceuticals
Mylan
Probiomed
TRPharma
Zenotech Laboratories
Segment by Type
500mg
100mg
Other
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Rituximab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Rituximab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Rituximab Biosimilars Market Overview
1.1 Product Overview and Scope of Rituximab Biosimilars
1.2 Rituximab Biosimilars Segment by Type
1.2.1 Global Rituximab Biosimilars Market Value Comparison by Type (2024-2030)
1.2.2 500mg
1.2.3 100mg
1.2.4 Other
1.3 Rituximab Biosimilars Segment by Application
1.3.1 Global Rituximab Biosimilars Market Value by Application: (2024-2030)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.4 Global Rituximab Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Rituximab Biosimilars Revenue 2019-2030
1.4.2 Global Rituximab Biosimilars Sales 2019-2030
1.4.3 Global Rituximab Biosimilars Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Rituximab Biosimilars Market Competition by Manufacturers
2.1 Global Rituximab Biosimilars Sales Market Share by Manufacturers (2019-2024)
2.2 Global Rituximab Biosimilars Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Rituximab Biosimilars Average Price by Manufacturers (2019-2024)
2.4 Global Rituximab Biosimilars Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Rituximab Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Rituximab Biosimilars, Product Type & Application
2.7 Rituximab Biosimilars Market Competitive Situation and Trends
2.7.1 Rituximab Biosimilars Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Rituximab Biosimilars Players Market Share by Revenue
2.7.3 Global Rituximab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Rituximab Biosimilars Retrospective Market Scenario by Region
3.1 Global Rituximab Biosimilars Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Rituximab Biosimilars Global Rituximab Biosimilars Sales by Region: 2019-2030
3.2.1 Global Rituximab Biosimilars Sales by Region: 2019-2024
3.2.2 Global Rituximab Biosimilars Sales by Region: 2025-2030
3.3 Global Rituximab Biosimilars Global Rituximab Biosimilars Revenue by Region: 2019-2030
3.3.1 Global Rituximab Biosimilars Revenue by Region: 2019-2024
3.3.2 Global Rituximab Biosimilars Revenue by Region: 2025-2030
3.4 North America Rituximab Biosimilars Market Facts & Figures by Country
3.4.1 North America Rituximab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Rituximab Biosimilars Sales by Country (2019-2030)
3.4.3 North America Rituximab Biosimilars Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Rituximab Biosimilars Market Facts & Figures by Country
3.5.1 Europe Rituximab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Rituximab Biosimilars Sales by Country (2019-2030)
3.5.3 Europe Rituximab Biosimilars Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Rituximab Biosimilars Market Facts & Figures by Country
3.6.1 Asia Pacific Rituximab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Rituximab Biosimilars Sales by Country (2019-2030)
3.6.3 Asia Pacific Rituximab Biosimilars Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Rituximab Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Rituximab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Rituximab Biosimilars Sales by Country (2019-2030)
3.7.3 Latin America Rituximab Biosimilars Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Rituximab Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Rituximab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Rituximab Biosimilars Sales by Country (2019-2030)
3.8.3 Middle East and Africa Rituximab Biosimilars Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Rituximab Biosimilars Sales by Type (2019-2030)
4.1.1 Global Rituximab Biosimilars Sales by Type (2019-2024)
4.1.2 Global Rituximab Biosimilars Sales by Type (2025-2030)
4.1.3 Global Rituximab Biosimilars Sales Market Share by Type (2019-2030)
4.2 Global Rituximab Biosimilars Revenue by Type (2019-2030)
4.2.1 Global Rituximab Biosimilars Revenue by Type (2019-2024)
4.2.2 Global Rituximab Biosimilars Revenue by Type (2025-2030)
4.2.3 Global Rituximab Biosimilars Revenue Market Share by Type (2019-2030)
4.3 Global Rituximab Biosimilars Price by Type (2019-2030)
5 Segment by Application
5.1 Global Rituximab Biosimilars Sales by Application (2019-2030)
5.1.1 Global Rituximab Biosimilars Sales by Application (2019-2024)
5.1.2 Global Rituximab Biosimilars Sales by Application (2025-2030)
5.1.3 Global Rituximab Biosimilars Sales Market Share by Application (2019-2030)
5.2 Global Rituximab Biosimilars Revenue by Application (2019-2030)
5.2.1 Global Rituximab Biosimilars Revenue by Application (2019-2024)
5.2.2 Global Rituximab Biosimilars Revenue by Application (2025-2030)
5.2.3 Global Rituximab Biosimilars Revenue Market Share by Application (2019-2030)
5.3 Global Rituximab Biosimilars Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Rituximab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen Rituximab Biosimilars Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 AryoGen Pharmed
6.2.1 AryoGen Pharmed Corporation Information
6.2.2 AryoGen Pharmed Description and Business Overview
6.2.3 AryoGen Pharmed Rituximab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AryoGen Pharmed Rituximab Biosimilars Product Portfolio
6.2.5 AryoGen Pharmed Recent Developments/Updates
6.3 Biocad
6.3.1 Biocad Corporation Information
6.3.2 Biocad Description and Business Overview
6.3.3 Biocad Rituximab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biocad Rituximab Biosimilars Product Portfolio
6.3.5 Biocad Recent Developments/Updates
6.4 Cadila Pharmaceuticals
6.4.1 Cadila Pharmaceuticals Corporation Information
6.4.2 Cadila Pharmaceuticals Description and Business Overview
6.4.3 Cadila Pharmaceuticals Rituximab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Cadila Pharmaceuticals Rituximab Biosimilars Product Portfolio
6.4.5 Cadila Pharmaceuticals Recent Developments/Updates
6.5 Celltrion
6.5.1 Celltrion Corporation Information
6.5.2 Celltrion Description and Business Overview
6.5.3 Celltrion Rituximab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Celltrion Rituximab Biosimilars Product Portfolio
6.5.5 Celltrion Recent Developments/Updates
6.6 Dr Reddy’s Laboratories
6.6.1 Dr Reddy’s Laboratories Corporation Information
6.6.2 Dr Reddy’s Laboratories Description and Business Overview
6.6.3 Dr Reddy’s Laboratories Rituximab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Dr Reddy’s Laboratories Rituximab Biosimilars Product Portfolio
6.6.5 Dr Reddy’s Laboratories Recent Developments/Updates
6.7 Teva
6.6.1 Teva Corporation Information
6.6.2 Teva Description and Business Overview
6.6.3 Teva Rituximab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Teva Rituximab Biosimilars Product Portfolio
6.7.5 Teva Recent Developments/Updates
6.8 Hetero Group
6.8.1 Hetero Group Corporation Information
6.8.2 Hetero Group Description and Business Overview
6.8.3 Hetero Group Rituximab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hetero Group Rituximab Biosimilars Product Portfolio
6.8.5 Hetero Group Recent Developments/Updates
6.9 Innovent Biologics
6.9.1 Innovent Biologics Corporation Information
6.9.2 Innovent Biologics Description and Business Overview
6.9.3 Innovent Biologics Rituximab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Innovent Biologics Rituximab Biosimilars Product Portfolio
6.9.5 Innovent Biologics Recent Developments/Updates
6.10 Intas Biopharmaceuticals
6.10.1 Intas Biopharmaceuticals Corporation Information
6.10.2 Intas Biopharmaceuticals Description and Business Overview
6.10.3 Intas Biopharmaceuticals Rituximab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Intas Biopharmaceuticals Rituximab Biosimilars Product Portfolio
6.10.5 Intas Biopharmaceuticals Recent Developments/Updates
6.11 Mylan
6.11.1 Mylan Corporation Information
6.11.2 Mylan Rituximab Biosimilars Description and Business Overview
6.11.3 Mylan Rituximab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Mylan Rituximab Biosimilars Product Portfolio
6.11.5 Mylan Recent Developments/Updates
6.12 Probiomed
6.12.1 Probiomed Corporation Information
6.12.2 Probiomed Rituximab Biosimilars Description and Business Overview
6.12.3 Probiomed Rituximab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Probiomed Rituximab Biosimilars Product Portfolio
6.12.5 Probiomed Recent Developments/Updates
6.13 TRPharma
6.13.1 TRPharma Corporation Information
6.13.2 TRPharma Rituximab Biosimilars Description and Business Overview
6.13.3 TRPharma Rituximab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.13.4 TRPharma Rituximab Biosimilars Product Portfolio
6.13.5 TRPharma Recent Developments/Updates
6.14 Zenotech Laboratories
6.14.1 Zenotech Laboratories Corporation Information
6.14.2 Zenotech Laboratories Rituximab Biosimilars Description and Business Overview
6.14.3 Zenotech Laboratories Rituximab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Zenotech Laboratories Rituximab Biosimilars Product Portfolio
6.14.5 Zenotech Laboratories Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Rituximab Biosimilars Industry Chain Analysis
7.2 Rituximab Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Rituximab Biosimilars Production Mode & Process
7.4 Rituximab Biosimilars Sales and Marketing
7.4.1 Rituximab Biosimilars Sales Channels
7.4.2 Rituximab Biosimilars Distributors
7.5 Rituximab Biosimilars Customers
8 Rituximab Biosimilars Market Dynamics
8.1 Rituximab Biosimilars Industry Trends
8.2 Rituximab Biosimilars Market Drivers
8.3 Rituximab Biosimilars Market Challenges
8.4 Rituximab Biosimilars Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Rituximab Biosimilars Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Rituximab Biosimilars Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Rituximab Biosimilars Market Competitive Situation by Manufacturers in 2023
Table 4. Global Rituximab Biosimilars Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Rituximab Biosimilars Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Rituximab Biosimilars Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Rituximab Biosimilars Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Rituximab Biosimilars Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Rituximab Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Rituximab Biosimilars, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Rituximab Biosimilars, Product Type & Application
Table 12. Global Key Manufacturers of Rituximab Biosimilars, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Rituximab Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rituximab Biosimilars as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Rituximab Biosimilars Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Rituximab Biosimilars Sales by Region (2019-2024) & (K Units)
Table 18. Global Rituximab Biosimilars Sales Market Share by Region (2019-2024)
Table 19. Global Rituximab Biosimilars Sales by Region (2025-2030) & (K Units)
Table 20. Global Rituximab Biosimilars Sales Market Share by Region (2025-2030)
Table 21. Global Rituximab Biosimilars Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Rituximab Biosimilars Revenue Market Share by Region (2019-2024)
Table 23. Global Rituximab Biosimilars Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Rituximab Biosimilars Revenue Market Share by Region (2025-2030)
Table 25. North America Rituximab Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Rituximab Biosimilars Sales by Country (2019-2024) & (K Units)
Table 27. North America Rituximab Biosimilars Sales by Country (2025-2030) & (K Units)
Table 28. North America Rituximab Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Rituximab Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Rituximab Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Rituximab Biosimilars Sales by Country (2019-2024) & (K Units)
Table 32. Europe Rituximab Biosimilars Sales by Country (2025-2030) & (K Units)
Table 33. Europe Rituximab Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Rituximab Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Rituximab Biosimilars Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Rituximab Biosimilars Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Rituximab Biosimilars Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Rituximab Biosimilars Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Rituximab Biosimilars Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Rituximab Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Rituximab Biosimilars Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Rituximab Biosimilars Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Rituximab Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Rituximab Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Rituximab Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Rituximab Biosimilars Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Rituximab Biosimilars Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Rituximab Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Rituximab Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Rituximab Biosimilars Sales (K Units) by Type (2019-2024)
Table 51. Global Rituximab Biosimilars Sales (K Units) by Type (2025-2030)
Table 52. Global Rituximab Biosimilars Sales Market Share by Type (2019-2024)
Table 53. Global Rituximab Biosimilars Sales Market Share by Type (2025-2030)
Table 54. Global Rituximab Biosimilars Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Rituximab Biosimilars Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Rituximab Biosimilars Revenue Market Share by Type (2019-2024)
Table 57. Global Rituximab Biosimilars Revenue Market Share by Type (2025-2030)
Table 58. Global Rituximab Biosimilars Price (US$/Unit) by Type (2019-2024)
Table 59. Global Rituximab Biosimilars Price (US$/Unit) by Type (2025-2030)
Table 60. Global Rituximab Biosimilars Sales (K Units) by Application (2019-2024)
Table 61. Global Rituximab Biosimilars Sales (K Units) by Application (2025-2030)
Table 62. Global Rituximab Biosimilars Sales Market Share by Application (2019-2024)
Table 63. Global Rituximab Biosimilars Sales Market Share by Application (2025-2030)
Table 64. Global Rituximab Biosimilars Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Rituximab Biosimilars Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Rituximab Biosimilars Revenue Market Share by Application (2019-2024)
Table 67. Global Rituximab Biosimilars Revenue Market Share by Application (2025-2030)
Table 68. Global Rituximab Biosimilars Price (US$/Unit) by Application (2019-2024)
Table 69. Global Rituximab Biosimilars Price (US$/Unit) by Application (2025-2030)
Table 70. Amgen Corporation Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen Rituximab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Amgen Rituximab Biosimilars Product
Table 74. Amgen Recent Developments/Updates
Table 75. AryoGen Pharmed Corporation Information
Table 76. AryoGen Pharmed Description and Business Overview
Table 77. AryoGen Pharmed Rituximab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. AryoGen Pharmed Rituximab Biosimilars Product
Table 79. AryoGen Pharmed Recent Developments/Updates
Table 80. Biocad Corporation Information
Table 81. Biocad Description and Business Overview
Table 82. Biocad Rituximab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Biocad Rituximab Biosimilars Product
Table 84. Biocad Recent Developments/Updates
Table 85. Cadila Pharmaceuticals Corporation Information
Table 86. Cadila Pharmaceuticals Description and Business Overview
Table 87. Cadila Pharmaceuticals Rituximab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Cadila Pharmaceuticals Rituximab Biosimilars Product
Table 89. Cadila Pharmaceuticals Recent Developments/Updates
Table 90. Celltrion Corporation Information
Table 91. Celltrion Description and Business Overview
Table 92. Celltrion Rituximab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Celltrion Rituximab Biosimilars Product
Table 94. Celltrion Recent Developments/Updates
Table 95. Dr Reddy’s Laboratories Corporation Information
Table 96. Dr Reddy’s Laboratories Description and Business Overview
Table 97. Dr Reddy’s Laboratories Rituximab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Dr Reddy’s Laboratories Rituximab Biosimilars Product
Table 99. Dr Reddy’s Laboratories Recent Developments/Updates
Table 100. Teva Corporation Information
Table 101. Teva Description and Business Overview
Table 102. Teva Rituximab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Teva Rituximab Biosimilars Product
Table 104. Teva Recent Developments/Updates
Table 105. Hetero Group Corporation Information
Table 106. Hetero Group Description and Business Overview
Table 107. Hetero Group Rituximab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Hetero Group Rituximab Biosimilars Product
Table 109. Hetero Group Recent Developments/Updates
Table 110. Innovent Biologics Corporation Information
Table 111. Innovent Biologics Description and Business Overview
Table 112. Innovent Biologics Rituximab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Innovent Biologics Rituximab Biosimilars Product
Table 114. Innovent Biologics Recent Developments/Updates
Table 115. Intas Biopharmaceuticals Corporation Information
Table 116. Intas Biopharmaceuticals Description and Business Overview
Table 117. Intas Biopharmaceuticals Rituximab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Intas Biopharmaceuticals Rituximab Biosimilars Product
Table 119. Intas Biopharmaceuticals Recent Developments/Updates
Table 120. Mylan Corporation Information
Table 121. Mylan Description and Business Overview
Table 122. Mylan Rituximab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Mylan Rituximab Biosimilars Product
Table 124. Mylan Recent Developments/Updates
Table 125. Probiomed Corporation Information
Table 126. Probiomed Description and Business Overview
Table 127. Probiomed Rituximab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Probiomed Rituximab Biosimilars Product
Table 129. Probiomed Recent Developments/Updates
Table 130. TRPharma Corporation Information
Table 131. TRPharma Description and Business Overview
Table 132. TRPharma Rituximab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. TRPharma Rituximab Biosimilars Product
Table 134. TRPharma Recent Developments/Updates
Table 135. Zenotech Laboratories Corporation Information
Table 136. Zenotech Laboratories Description and Business Overview
Table 137. Zenotech Laboratories Rituximab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Zenotech Laboratories Rituximab Biosimilars Product
Table 139. Zenotech Laboratories Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Rituximab Biosimilars Distributors List
Table 143. Rituximab Biosimilars Customers List
Table 144. Rituximab Biosimilars Market Trends
Table 145. Rituximab Biosimilars Market Drivers
Table 146. Rituximab Biosimilars Market Challenges
Table 147. Rituximab Biosimilars Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Rituximab Biosimilars
Figure 2. Global Rituximab Biosimilars Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Rituximab Biosimilars Market Share by Type in 2023 & 2030
Figure 4. 500mg Product Picture
Figure 5. 100mg Product Picture
Figure 6. Other Product Picture
Figure 7. Global Rituximab Biosimilars Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Rituximab Biosimilars Market Share by Application in 2023 & 2030
Figure 9. Hospital Pharmacy
Figure 10. Retail Pharmacy
Figure 11. Global Rituximab Biosimilars Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Rituximab Biosimilars Market Size (2019-2030) & (US$ Million)
Figure 13. Global Rituximab Biosimilars Sales (2019-2030) & (K Units)
Figure 14. Global Rituximab Biosimilars Average Price (US$/Unit) & (2019-2030)
Figure 15. Rituximab Biosimilars Report Years Considered
Figure 16. Rituximab Biosimilars Sales Share by Manufacturers in 2023
Figure 17. Global Rituximab Biosimilars Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Rituximab Biosimilars Players: Market Share by Revenue in 2023
Figure 19. Rituximab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Rituximab Biosimilars Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Rituximab Biosimilars Sales Market Share by Country (2019-2030)
Figure 22. North America Rituximab Biosimilars Revenue Market Share by Country (2019-2030)
Figure 23. United States Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Rituximab Biosimilars Sales Market Share by Country (2019-2030)
Figure 26. Europe Rituximab Biosimilars Revenue Market Share by Country (2019-2030)
Figure 27. Germany Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Rituximab Biosimilars Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Rituximab Biosimilars Revenue Market Share by Region (2019-2030)
Figure 34. China Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Rituximab Biosimilars Sales Market Share by Country (2019-2030)
Figure 44. Latin America Rituximab Biosimilars Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Rituximab Biosimilars Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Rituximab Biosimilars Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE Rituximab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Rituximab Biosimilars by Type (2019-2030)
Figure 54. Global Revenue Market Share of Rituximab Biosimilars by Type (2019-2030)
Figure 55. Global Rituximab Biosimilars Price (US$/Unit) by Type (2019-2030)
Figure 56. Global Sales Market Share of Rituximab Biosimilars by Application (2019-2030)
Figure 57. Global Revenue Market Share of Rituximab Biosimilars by Application (2019-2030)
Figure 58. Global Rituximab Biosimilars Price (US$/Unit) by Application (2019-2030)
Figure 59. Rituximab Biosimilars Value Chain
Figure 60. Rituximab Biosimilars Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
